Revisiting CLEC 12A as leukaemic stem cell marker in AML : highlighting the necessity of precision diagnostics in patients eligible for targeted therapy

Abstract excerpt

Targeted therapy directed against rare disease-propagating leukaemic stem cells (LSCs) is a promising prospect for improving the outcome of acute myeloid leukaemia (AML) patients. Thus, distinguishing LSCs from normal haematopoietic stem and progenitor cells (HSPCs) is essential. The CLEC12A receptor has been proposed as a specific marker of LSCs, and consequently as an appealing treatment target. To explore the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Epigenetics and DNA Methylation
• Share to Hematopoietic Stem Cell Transplantation